The latest price target for Palisade Bio (NASDAQ:PALI) was reported by B. Riley Securities on January 9, 2026. The analyst firm set a price target for $7.00 expecting PALI to rise to within 12 months (a possible 319.16% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Palisade Bio (NASDAQ:PALI) was provided by B. Riley Securities, and Palisade Bio initiated their buy rating.

The last upgrade for Palisade Bio Inc happened on November 17, 2023 when Maxim Group raised their price target to $1.5. Maxim Group previously had a hold for Palisade Bio Inc.

There is no last downgrade for Palisade Bio.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Palisade Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Palisade Bio was filed on January 9, 2026 so you should expect the next rating to be made available sometime around January 9, 2027.

While ratings are subjective and will change, the latest Palisade Bio (PALI) rating was a initiated with a price target of $0.00 to $7.00. The current price Palisade Bio (PALI) is trading at is $1.67, which is within the analyst’s predicted range.